December 1, 2012Obstetrical & Gynecological Survey
Aspirin for Preventing the Recurrence of Venous Thromboembolism
Key result
Aspirin therapy given after discontinuation of anticoagulants for unprovoked venous thromboembolism reduced VTE recurrence compared with placebo (HR 0.58; 95% CI 0.36-0.93; P=0.02).
Why the study?
Does aspirin 100 mg once-daily reduce the recurrence of venous thromboembolism in patients who have completed 6 to 18 months of anticoagulant treatment for first-ever unprovoked venous thromboembolism?
Population
403 patients older than 18 years who had completed 6 to 18 months of anticoagulant treatment with vitamin K…
Comparison
Aspirin 100 mg oral once-daily for 2 years, with… vs Matching placebo once-daily for 2 years.
Design
RCT, randomized, double-blind
Follow-up
median 24.6 months
Authors
Discussion
Loading...
Member takes
Implication
Supports aspirin for extended secondary prevention in unprovoked VTE; confirms RCT benefit without major bleeding increase.
Study Design
Type
RCT (n=403)
Blinding
Double-blind
Randomization
randomized
Multicenter
Yes
Structured PICO
Does aspirin 100 mg once-daily reduce the recurrence of venous thromboembolism in patients who have completed 6 to 18 months of anticoagulant treatment for first-ever unprovoked venous thromboembolism?
P
Population
403 adults who completed 6 to 18 months of anticoagulant treatment for first-ever unprovoked venous thromboembolism, followed for a median of 24.6 months.
I
Intervention
Aspirin 100 mg oral once-daily for 2 years, with the option of extending the study treatment.
C
Comparator
Matching placebo once-daily for 2 years.
O
Outcome
Recurrence of venous thromboembolism during a median study period of 24.6 months.hard clinical
Main Result
Hazard Ratio: 0.58 (95% CI 0.36–0.93)
Absolute Event Rate: 6.6% vs 11.2%
p-value: p=0.02
Aspirin 100 mg daily significantly reduces the long-term risk of recurrent venous thromboembolism after discontinuation of oral anticoagulants, without increasing the risk of major bleeding.
Cite This Study
Becattini et al. (2012) conducted an RCT in Unprovoked venous thromboembolism (n=403). Aspirin vs. Placebo was evaluated on Recurrence of venous thromboembolism (HR 0.58, 95% CI 0.36-0.93, p=0.02). Aspirin therapy given after discontinuation of anticoagulants for unprovoked venous thromboembolism reduced VTE recurrence compared with placebo (HR 0.58; 95% CI 0.36-0.93; P=0.02).